(Q43114749)

14 November 2017

title

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. (English)

1 reference

adult attention deficit hyperactivity disorder

14 November 2017

main subject

1 reference

8

Sabine Herpertz

1 reference

14 November 2017

5

Barbara Alm

1 reference

14 November 2017

7

Alexandra Philipsen

1 reference

14 November 2017

Michael Rösler

1

1 reference

14 November 2017

Wolfgang Retz

2

1 reference

14 November 2017

Roland Fischer

3

1 reference

14 November 2017

Claudia Ose

4

1 reference

14 November 2017

Jürgen Deckert

6

1 reference

14 November 2017

Richard Ammer

9

1 reference

14 November 2017

publication date

1 August 2010

1 reference

World Journal of Biological Psychiatry

14 November 2017

published in

1 reference

14 November 2017

volume

11

1 reference

14 November 2017

issue

5

1 reference

14 November 2017

page(s)

709-718

1 reference

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Diagnostic controversies in adult attention deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Adult attention deficit hyperactivity disorder: moving beyond DSM-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Emotional dysregulation in adult ADHD and response to atomoxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Psychopathological rating scales for diagnostic use in adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

The relation between disinhibition and emotion regulation in boys with attention deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622971003624197

10.3109/15622971003624197

21 January 2018

Identifiers

DOI

1 reference

14 November 2017

1 reference